Bispecific Antibody Competitive Landscape 2025: Providing Strategic Insights Into 180+ Companies and 250+ Drugs by DelveInsight

[Albany, United States] DelveInsight, a leading business consulting and market research firm focused on life sciences, announces the release of its latest publication, "Bispecific Antibody - Competitive Landscape, 2025." This in-depth report provides strategic intelligence, covering over 180 companies and more than 250 drugs in the bispecific antibody market. The study offers therapeutic assessments by product type, clinical stage, route of administration, molecule type, and highlights inactive pipeline products, giving pharmaceutical stakeholders an unparalleled view of the global bispecific antibody competitive landscape.

Get exclusive access to the only report analyzing 180+ companies & 250+ drugs in the bispecific antibody space. Download the Report - https://www.delveinsight.com/report-store/bispecific-antibody-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Bispecific Antibodies in Oncology Pipeline Summary
• Companies across the globe are diligently working toward developing novel Bispecific Antibody treatment therapies with a considerable amount of success over the years.
• The Bispecific Antibody pipeline report provides the total potential number of patients in the indications, such as Acute Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Multiple Myeloma, Non-small-cell Lung Cancer, Small-cell Lung Cancer, Biliary Tract Cancer, Breast Cancer, Gastric Cancer/Esophageal Cancer, Pancreatic Cancer, Colorectal Cancer, and others.
• In the US, the population eligible for treatment with bispecific antibodies in oncology was estimated to be approximately 895K cases.
• Key bispecific antibodies in oncology companies, such as I-MAB Biopharma, BMS, AstraZeneca, BioNTech, Genmab, Compass Therapeutics, Innovent, Regeneron Pharmaceuticals, Aurigene Oncology, Curis, Akeso, Summit Therapeutics, Roche, Merus, Adimab, Creative Biolabs, Amgen, Zymeworks, Xencor, Novo Nordisk, MacroGenics, and others, are developing novel bispecific antibodies in oncology that can be available in the bispecific antibodies in oncology market in the coming years.
• Some of the key bispecific antibodies in oncology in the clinical trials include Givastomig, Volrustomig, BNT327, Acasunlimab, Rilvegostomig, CTX-009, IBI363, REGN5459, CA-170, Ivonescimab, Odronextamab, MCLA-129, MIM8, MGD024, COLUMVI, RYBREVANT, and others.

Discover pipeline therapies, collaborations, and market-shaping deals before your competitors. Request Your Free Sample Today - https://www.delveinsight.com/sample-request/bispecific-antibody-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Understanding Bispecific Antibodies
The Science Behind Antibodies
Immunoglobulins (antibodies [Abs]) are key proteins of the adaptive immune system that defend the body against infections and foreign agents. Among these, IgG molecules-consisting of two light and two heavy chains-play a dominant role, offering monospecific and bivalent activity. Traditionally, antibodies carry two identical antigen-binding sites. However, the advent of bispecific antibodies (BsAbs) has transformed this field, enabling the design of molecules that can target two distinct antigens simultaneously.

Bispecific Antibody Functionality
Bispecific antibodies have unlocked the ability to redirect cytotoxic T lymphocytes toward tumor cells by binding to CD3 receptors on T cells and tumor-associated antigens like CD19, CD20, HER2, BCMA, CEA, and EpCAM. This dual-targeting capability enhances tumor cell killing while activating the immune system's natural defenses.

Beyond oncology, bispecific antibodies are making headway in osteoporosis, hemophilia, Alzheimer's disease, and autoimmune disorders. For instance:
• ACE910 (Hemophilia A): Reduces bleeding rates by binding blood-clotting factors IX and X.
• Osteoporosis therapies: Target Wnt pathway regulators such as sclerostin and Dkk1 to promote bone growth.
• Neurodegenerative candidates: Combine transferrin receptor targeting with BACE1 inhibition to cross the blood-brain barrier and reduce amyloid peptide accumulation in Alzheimer's.

Advantages Over Monospecific Therapies
Bispecific antibodies represent a leap forward compared to conventional monoclonal antibodies. Key benefits include:
• Higher specificity and efficacy: Dual-target binding improves therapeutic potential.
• Cost-effectiveness: One BsAb can replace combination therapies with two monoclonals, lowering R&D and clinical trial costs.
• Resistance reduction: Targeting multiple receptors on a tumor cell mitigates the risk of resistance.
• Broader therapeutic reach: Expands treatment beyond oncology into inflammatory, autoimmune, and rare diseases.

Explore in-depth clinical, commercial, and scientific intelligence on the bispecific antibody market. Access the Report Now - https://www.delveinsight.com/report-store/bispecific-antibody-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Bispecific Antibody Competitive Landscape
• Janssen
• Amgen
• Akeso
• Zymeworks
• Roche
• IGM Biosciences
• MacroGenics
• Provention Bio
• Jiangsu Alphamab Biopharmaceuticals
• Sichuan Baili Pharmaceutical
• Regeneron Pharmaceuticals
• Boehringer Ingelheim

Bispecific Antibody Market Highlights: Strategic Collaborations & Developments
The "Bispecific Antibody - Competitive Landscape, 2025" report tracks significant business and scientific milestones shaping the global competitive field.
• LAVA Therapeutics N.V. & Merck & Co. (Jan 2024): Collaboration to study LAVA-1207 with KEYTRUDA® for metastatic prostate cancer.
• Biocytogen & Radiance Biopharma (Jan 2024): Exclusive license agreement on a novel HER2/TROP2 BsADC.
• Debiopharm & SunRock Biopharma (Jan 2024): Expanded licensing deal for HER3-EGFR bispecific ADCs.
• Pfizer & Seagen (Dec 2023): Pfizer's USD 43 billion acquisition doubled its oncology pipeline, including bispecifics.
• NAYA Biosciences & ONK (Dec 2023): Research partnership exploring NK cell combinations with FLEX-NKTM bispecifics.
• I-Mab (Nov 2023): Preclinical poster presentations on innovative CD4/4-1BB bispecifics at SITC.
• Cantai Therapeutics (Nov 2023): Formation of biotech company focused on cytokine-targeting BsAbs for autoimmune diseases.
• Lonza & ABL Bio (Apr 2023): Development and manufacturing partnership for BsAbs in oncology and neurodegeneration.

Learn how leading players like Amgen, Roche, AstraZeneca, and Regeneron are shaping the Bispecific Antibody market - https://www.delveinsight.com/sample-request/bispecific-antibody-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Bispecific Antibody Marketed Therapies: Company Profiles
Janssen (Johnson & Johnson) - Amivantamab (RYBREVANT®)
• Target: EGFR & MET
• Indication: NSCLC with EGFR Exon 20 insertion mutations
• Significance: First FDA-approved therapy developed using Genmab's DuoBody® technology platform.

Amgen - Blinatumomab (BLINCYTO®)
• Target: CD19 & CD3 (BiTE® platform)
• Indications: Acute lymphoblastic leukemia, B-cell lymphomas
• Importance: First BiTE antibody; approved for multiple hematological malignancies with orphan drug designation.

Pipeline Therapies: Company Profiles
AstraZeneca - Gefurulimab
• Humanized bispecific antibody against C5 & albumin.
• Potential in autoimmune diseases through complement pathway inhibition.

Sichuan Baili Pharmaceutical - SI-B001
• Targets: EGFR & HER3
• Stage: Phase III
• Demonstrated strong tumor-killing efficacy in early trials.

Innovent Biologics - IBI322
• Targets: CD47 & PD-L1
• Stage: Phase II
• Dual immune activation mechanism for hematological and solid tumors.

IGM Biosciences - Imvotamab
• IgM-based CD20 x CD3 bispecific antibody.
• Offers stronger binding and reduced cytokine release compared to IgG bispecifics.

MacroGenics - MGD024
• Targets: CD123 × CD3 (DART® platform).
• Designed to minimize cytokine-release syndrome while maintaining anti-leukemia activity.

See where your organization stands in the global bispecific antibody pipeline landscape. Download report now - https://www.delveinsight.com/sample-request/bispecific-antibody-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Bispecific Antibody Analytical Perspective by DelveInsight
The report goes beyond molecule-level science and provides commercial intelligence, including:
• Collaboration and licensing trends across industry and academia.
• Mergers & acquisitions reshaping the competitive landscape.
• Comparative company assessments by therapy area, clinical stage, and technology.
• Unmet needs and future opportunities for stakeholders.

Key Questions Addressed in Bispecific Antibody Pipeline Report
The report answers critical questions shaping the bispecific antibody market:
1. How many companies are developing bispecific antibody drugs?
2. What is the distribution of drugs across early, mid, and late-stage pipelines?
3. What are the key collaborations, licensing deals, and acquisitions driving innovation?
4. Which novel technologies are overcoming limitations of current antibody therapies?
5. What clinical studies are ongoing and what is their status?
6. Which drugs have received key designations and regulatory approvals?

Bispecific Antibody Future Outlook
The bispecific antibody market is global in scope, with R&D hubs in the United States, Europe, and Asia-Pacific. As regulatory frameworks evolve and new modalities emerge, BsAbs are poised to redefine cancer treatment and expand into autoimmune, neurodegenerative, and rare diseases.
DelveInsight forecasts that strategic collaborations, platform innovations, and expanding indications will drive substantial market growth in the coming decade.

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.